Also known as: SLU-PP-915, SLUPP915, pan-ERR agonist SLU-PP-915, ERR agonist 10s
SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886).
Overview
At A Glance
SLU-PP-915 is a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, orphan nuclear receptors that drive transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle and are required for skele…
Overview
SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it. It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903). SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886). The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047). Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687). Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
2285432-92-8
Molecular Formula
C17H13BFNO3S
Molecular Mass
341.16 g/mol
Dosing & Protocols
Unlock the Dosing tab
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- Route
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Research
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Interactions
Contraindications
None can be stated from evidence, because no human has been studied. Mechanism-based caution applies broadly: ERR agonism alters mitochondrial and metabolic gene transcription across muscle, heart, kidney and liver (PMID: 37961903; PMID: 37717940), and no organ safety margin has been established in any species at doses relevant to human use. No reproductive, developmental, hepatic or renal safety data exist.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$139.99
$0.2333
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
SLU-PP-915 10 mg capsules (60) | capsule | 60 capsules (10 mg)● In Stock | $139.99BEST | $0.233 | — |
Tracking since Sep 7, 2026 · 1 data point
Vendors Selling SLU-PP-915
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAICAR (acadesine)
MetabolicPhase 3AICAR is a nucleoside analog of adenosine.
Amlexanox
MetabolicFDA ApprovedAmlexanox is an old anti-inflammatory drug with a second life.
Berberine
MetabolicPreclinicalBerberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi).
Cardarine (GW501516)
MetabolicDiscontinuedCardarine is the market name for GW501516, a synthetic agonist of the nuclear receptor PPAR-delta developed by GlaxoSmithKline as a treatment for low HDL cholesterol and the lipid problems that travel with metabolic syndrome.
Metformin
MetabolicPreclinicalMetformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually.
Sobetirome (GC-1)
MetabolicDiscontinuedSobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548).
View Full Dosage Guide →
Protocols, calculator & safety for SLU-PP-915
Research Score
0 PubMed results
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Not established in humans; in mice it is orally bioavailable and active by both oral and intraperitoneal routes, unlike its predecessor SLU-PP-332 (PMID: 41421047)
Molecular Weight
341.16 g/mol
Administration
Oral (rodent studies), Intraperitoneal injection (rodent studies)
CAS Number
2285432-92-8
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is SLU-PP-915 used for in research?
SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It was reported in 2023 by John Walker, Thomas Burris and colleagues as the lead of a new chemical series of pan-ERR agonists (PMID: 37421886). It has never been in a human being. No company has taken it into development and no regulator has reviewed it.
It is the follow-up to SLU-PP-332, the compound that got press coverage as exercise in a pill. SLU-PP-332 activates all three ERR subtypes and, in mice, increased type IIa oxidative muscle fibers, enhanced running endurance and triggered the gene expression program that a single bout of aerobic exercise produces (PMID: 36988910). In diet-induced obese mice it raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity (PMID: 37739806). Related pan-ERR agonists improved cardiac fatty acid metabolism and mitochondrial function in heart failure models (PMID: 37961903).
SLU-PP-915 exists because SLU-PP-332 has a practical flaw: it is not orally bioavailable, so mice had to be injected. The medicinal chemistry work replaced a phenol or aniline group with a boronic acid, which held potency while improving metabolic stability in liver microsome assays, and the resulting compound raised expression of the ERR target genes PGC-1alpha, LDHA, DDIT4 and PDK4 both in cells and in animals (PMID: 37421886).
The 2025 pharmacology paper is the key one. SLU-PP-915 increased aerobic exercise performance in mice, both running distance and duration, to a similar degree as SLU-PP-332 when injected, and held comparable effect when given by mouth after adjusting for systemic exposure. Both compounds strongly induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding actual treadmill running in some muscles, and SLU-PP-915 combined with training raised mitochondrial gene expression further than either alone (PMID: 41421047).
Everything above is mice. There is no human pharmacokinetic study, no safety study, no dose, and no published record of any person taking it. Anti-doping chemists have already characterized its in vitro metabolites in human liver preparations specifically because they expect it to be misused before it is ever studied properly (PMID: 41588687).
Capsules sold as SLU-PP-915 are a laboratory compound that reached a peer-reviewed pharmacology paper in 2025 and skipped every step between that paper and a person swallowing it.
What forms does SLU-PP-915 come in?
SLU-PP-915 is available in capsule form.
How much does SLU-PP-915 cost?
Prices start at $139.99 across 1 vendor.
How do I compare SLU-PP-915 vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View AllAICAR (acadesine)
MetabolicPhase 3AICAR is a nucleoside analog of adenosine.
Amlexanox
MetabolicFDA ApprovedAmlexanox is an old anti-inflammatory drug with a second life.
Berberine
MetabolicPreclinicalBerberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi).
Cardarine (GW501516)
MetabolicDiscontinuedCardarine is the market name for GW501516, a synthetic agonist of the nuclear receptor PPAR-delta developed by GlaxoSmithKline as a treatment for low HDL cholesterol and the lipid problems that travel with metabolic syndrome.
Metformin
MetabolicPreclinicalMetformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually.
Sobetirome (GC-1)
MetabolicDiscontinuedSobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548).
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.